• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在艰难梭菌感染的人体肠道模型中，托氟沙星对细胞毒素的中和无效。

Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection.

作者信息

Baines Simon D, Freeman Jane, Wilcox Mark H

机构信息

Department of Microbiology, Institute of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, United Kingdom.

出版信息

Antimicrob Agents Chemother. 2009 May;53(5):2202-4. doi: 10.1128/AAC.01085-08. Epub 2009 Feb 17.

DOI:10.1128/AAC.01085-08
PMID:19223641
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2681510/
Abstract

The efficacy of tolevamer, a nonantimicrobial styrene derivative toxin-binding agent, in treating simulated Clostridium difficile infection in an in vitro human gut model was investigated. Tolevamer reduced neither the duration nor magnitude of cytotoxin activity by C. difficile, reflecting poor efficacy observed in recent phase III clinical trials.

摘要

研究了一种非抗菌性苯乙烯衍生物毒素结合剂托纳美在体外人肠道模型中治疗模拟艰难梭菌感染的疗效。托纳美既未缩短艰难梭菌细胞毒素活性的持续时间，也未降低其活性强度，这反映出在近期的III期临床试验中观察到的疗效不佳。

相似文献

1
Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection.在艰难梭菌感染的人体肠道模型中，托氟沙星对细胞毒素的中和无效。
Antimicrob Agents Chemother. 2009 May;53(5):2202-4. doi: 10.1128/AAC.01085-08. Epub 2009 Feb 17.
2
Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile.托利万古，一种阴离子聚合物，可中和艰难梭菌BI/027菌株产生的毒素。
Antimicrob Agents Chemother. 2008 Jun;52(6):2190-5. doi: 10.1128/AAC.00041-08. Epub 2008 Apr 7.
3
Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea.持续临床反应作为艰难梭菌相关性腹泻治疗试验的一个终点指标。
Antimicrob Agents Chemother. 2012 Aug;56(8):4043-5. doi: 10.1128/AAC.00605-12. Epub 2012 May 21.
4
Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.托利霉素，一种新型非抗生素聚合物，与万古霉素治疗轻度至中度严重艰难梭菌相关性腹泻的疗效比较。
Clin Infect Dis. 2006 Aug 15;43(4):411-20. doi: 10.1086/506349. Epub 2006 Jul 11.
5
GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis.GT160 - 246，一种用于治疗艰难梭菌结肠炎的毒素结合聚合物。
Antimicrob Agents Chemother. 2001 Aug;45(8):2340-7. doi: 10.1128/AAC.45.8.2340-2347.2001.
6
Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties.综述文章：托伐美（tolevamer），一种新型毒素结合聚合物：临床前药理学及物理化学性质概述
Aliment Pharmacol Ther. 2006 Dec;24(11-12):1525-34. doi: 10.1111/j.1365-2036.2006.03157.x.
7
Tolevamer, an orally administered, toxin-binding polymer for Clostridium difficile-associated diarrhea.托利霉素，一种口服的用于治疗艰难梭菌相关性腹泻的毒素结合聚合物。
Curr Opin Investig Drugs. 2008 Aug;9(8):913-24.
8
SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model.SMT19969 作为艰难梭菌感染的治疗药物：使用传统药敏试验和体外肠道模型对抗菌活性的评估
J Antimicrob Chemother. 2015 Jan;70(1):182-9. doi: 10.1093/jac/dku324. Epub 2014 Sep 3.
9
Microbial and metabolic interactions between the gastrointestinal tract and Clostridium difficile infection.肠道微生物与代谢相互作用及其与艰难梭菌感染的关系。
Gut Microbes. 2014 Jan-Feb;5(1):86-95. doi: 10.4161/gmic.27131. Epub 2013 Dec 11.
10
Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer.艰难梭菌的毒素结合治疗：一项综述，包括托利瓦默的研究报告
Int J Antimicrob Agents. 2009 Jan;33(1):4-7. doi: 10.1016/j.ijantimicag.2008.07.011. Epub 2008 Sep 18.

引用本文的文献

1
Non-Toxigenic Strain E4 (NTCD-E4) Prevents Establishment of Primary Infection by Epidemic PCR Ribotype 027 in an In Vitro Human Gut Model.非产毒菌株E4（NTCD-E4）在体外人肠道模型中可防止流行PCR核糖型027引发原发性感染。
Antibiotics (Basel). 2023 Feb 22;12(3):435. doi: 10.3390/antibiotics12030435.
2
Trehalose-Induced Remodelling of the Human Microbiota Affects Infection Outcome in an Colonic Model: A Pilot Study.海藻糖诱导的人类微生物组重塑影响结肠模型中的感染结局：一项初步研究。
Front Cell Infect Microbiol. 2021 Jul 2;11:670935. doi: 10.3389/fcimb.2021.670935. eCollection 2021.
3
Treatment of Clostridium difficile Infection with a Small-Molecule Inhibitor of Toxin UDP-Glucose Hydrolysis Activity.治疗艰难梭菌感染的小分子抑制剂的毒素 UDP-葡萄糖水解活性。
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.00107-18. Print 2018 May.
4
A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection.艰难梭菌感染的实验性和非标签疗法综述
Infect Dis Ther. 2017 Mar;6(1):1-35. doi: 10.1007/s40121-016-0140-z. Epub 2016 Dec 1.
5
Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection.艰难梭菌的抗药性和耐药性降低：对艰难梭菌感染的诱导、治疗和复发的潜在影响。
Antibiotics (Basel). 2015 Jul 10;4(3):267-98. doi: 10.3390/antibiotics4030267.
6
SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model.SMT19969 作为艰难梭菌感染的治疗药物：使用传统药敏试验和体外肠道模型对抗菌活性的评估
J Antimicrob Chemother. 2015 Jan;70(1):182-9. doi: 10.1093/jac/dku324. Epub 2014 Sep 3.
7
The host immune response to Clostridium difficile infection.宿主对艰难梭菌感染的免疫反应。
Ther Adv Infect Dis. 2013 Feb;1(1):19-35. doi: 10.1177/2049936112472173.
8
Clostridium difficile and the microbiota.艰难梭菌与微生物群
J Clin Invest. 2014 Oct;124(10):4182-9. doi: 10.1172/JCI72336. Epub 2014 Jul 18.
9
Clinical update for the diagnosis and treatment of Clostridium difficile infection.艰难梭菌感染的诊断与治疗临床进展
World J Gastrointest Pharmacol Ther. 2014 Feb 6;5(1):1-26. doi: 10.4292/wjgpt.v5.i1.1.
10
Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.艰难梭菌感染治疗方法的研究进展：临床和药物化学综述。
Curr Top Med Chem. 2014;14(1):152-75. doi: 10.2174/1568026613666131113154753.

本文引用的文献

1
Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model.在人体肠道模型中，奥硝唑与万古霉素治疗克林霉素诱导的艰难梭菌PCR核糖体分型027感染的比较。
J Antimicrob Chemother. 2008 Nov;62(5):1078-85. doi: 10.1093/jac/dkn358. Epub 2008 Sep 4.
2
Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.艰难梭菌PCR核糖体分型027和001在人体肠道模型中暴露于氟喹诺酮类药物的影响。
Antimicrob Agents Chemother. 2009 Feb;53(2):412-20. doi: 10.1128/AAC.00306-08. Epub 2008 Aug 18.
3
Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.甲硝唑和万古霉素治疗艰难梭菌相关性疾病的临床及微生物学反应比较
Clin Infect Dis. 2008 Jul 1;47(1):56-62. doi: 10.1086/588293.
4
Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile.托利万古，一种阴离子聚合物，可中和艰难梭菌BI/027菌株产生的毒素。
Antimicrob Agents Chemother. 2008 Jun;52(6):2190-5. doi: 10.1128/AAC.00041-08. Epub 2008 Apr 7.
5
Treatment of Clostridium difficile infection.艰难梭菌感染的治疗
Clin Infect Dis. 2008 Jan 15;46 Suppl 1:S32-42. doi: 10.1086/521860.
6
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.万古霉素与甲硝唑治疗艰难梭菌相关性腹泻的比较，按疾病严重程度分层
Clin Infect Dis. 2007 Aug 1;45(3):302-7. doi: 10.1086/519265. Epub 2007 Jun 19.
7
Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model.甲硝唑对人肠道模型中流行的艰难梭菌PCR核糖体分型001和027生长及毒素产生的影响
J Antimicrob Chemother. 2007 Jul;60(1):83-91. doi: 10.1093/jac/dkm113. Epub 2007 May 5.
8
Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model.在人体肠道模型中，替加环素不会诱导流行的艰难梭菌菌株增殖或产生细胞毒素。
J Antimicrob Chemother. 2006 Nov;58(5):1062-5. doi: 10.1093/jac/dkl364. Epub 2006 Oct 8.
9
Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.托利霉素，一种新型非抗生素聚合物，与万古霉素治疗轻度至中度严重艰难梭菌相关性腹泻的疗效比较。
Clin Infect Dis. 2006 Aug 15;43(4):411-20. doi: 10.1086/506349. Epub 2006 Jul 11.
10
Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection.瑞莫拉宁与万古霉素在克林霉素诱导的艰难梭菌感染的体外和体内模型中的疗效比较。
J Antimicrob Chemother. 2005 Oct;56(4):717-25. doi: 10.1093/jac/dki321. Epub 2005 Sep 5.